Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to -$78.2 million.

  • Nurix Therapeutics' Consolidated Net Income fell 3359.92% to -$78.2 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$264.5 million, marking a year-over-year decrease of 3662.16%. This contributed to the annual value of -$264.5 million for FY2025, which is 3662.16% down from last year.
  • As of Q4 2025, Nurix Therapeutics' Consolidated Net Income stood at -$78.2 million, which was down 3359.92% from -$86.4 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Consolidated Net Income high stood at -$24.3 million for Q1 2021, and its period low was -$86.4 million during Q3 2025.
  • Its 5-year average for Consolidated Net Income is -$45.0 million, with a median of -$43.0 million in 2022.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 44804.75% in 2021, then surged by 4652.76% in 2023.
  • Quarter analysis of 5 years shows Nurix Therapeutics' Consolidated Net Income stood at -$37.7 million in 2021, then decreased by 23.95% to -$46.7 million in 2022, then rose by 10.19% to -$42.0 million in 2023, then tumbled by 39.55% to -$58.5 million in 2024, then plummeted by 33.6% to -$78.2 million in 2025.
  • Its Consolidated Net Income was -$78.2 million in Q4 2025, compared to -$86.4 million in Q3 2025 and -$43.5 million in Q2 2025.